In this white paper, authored by Dr Sarah Moore, Head of Gene Therapy Discovery, Touchlight, we discuss major challenges and present approaches to improve overall functional titre, through the optimisation of upstream and downstream processing platforms, as well as strategies for eliminating the requirement for plasmid DNA, including the use of rapid and highly scalable platforms for manufacturing synthetic DNA as a viable alternative to address regulatory hurdles and achieve cost efficiencies.